Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια
The ultimate guide for Pharma Marketing
Champions
Ζητήστε
το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…
Παρασκευή 9 Μαρτίου 2012
Σχέδιο για την αλλαγή της συσκευασίας φαρμάκων
Σχέδιο για
την αλλαγή της συσκευασίας φαρμάκων τα οποία διατίθενται εξωνοσοκομειακά,
επεξεργάζεται το υπουργείο Υγείας προκειμένου να αντιμετωπίσει το φαινόμενο των
μεγάλων συσκευασιών με ποσότητες φαρμάκων που δεν είναι πάντοτε αναγκαίες για
τους ασθενείς.
Όπως
ανακοίνωσε ο υπουργός Υγείας Ανδρέας Λοβέρδος, ενημερώνοντας τις αρμόδιες
κοινοβουλευτικές επιτροπές, τα σενάρια που μελετώνται, περιλαμβάνουν αλλαγή
συσκευασιών, ώστε να υπάρχουν επιλογές στις αναγκαίες ποσότητες κάθε φαρμάκου ή
ακόμη και χορήγηση φαρμάκων από βάζα που θα υπάρχουν στα φαρμακεία και ο
φαρμακοποιός θα βάζει όσα χρειάζεται σε δική του συσκευασία προσθέτοντας την
απαιτούμενη ετικέτα.
Όπως
διευκρίνισε ο υπουργός, το σχέδιο δεν θα προλάβει να πάει στη Βουλή λόγω
εκλογών, αλλά εκείνος έχει δώσει εντολή να προετοιμαστεί ώστε να το βρει έτοιμο
όποιος τον διαδεχθεί στο υπουργείο.
Lilly launches new scheme to promote medical innovation
Lilly has
announced the launch of a new programme which aims to promote innovative
medical research on a global basis.
The Innovation Starts Here initiative will encompass a number of schemes aimed at accelerating the delivery of new medicines to patients, including the Lilly Research Awards Program and the Lilly Innovation Fellowship Awards.
Both of these programmes will see Lilly offering funding support and collaborative opportunities to academic researchers who are conducting studies that will support the company's drug development pipeline.
Lilly is also seeking to increase its own spending on innovative studies, having doubled its outlay on European research and development in the last decade.
Dr Jan Lundberg, executive vice-president for science and technology and president of Lilly Research Laboratories, said: "Finding innovative medicines that have clear, demonstrable value for those diseases where the unmet need is great ... is not only a scientific imperative, it's an economic one as well."
Last month, the company published its latest corporate responsibility report, showing that it was able to help more than 227,000 people through patient assistance programmes in 2010.
The Innovation Starts Here initiative will encompass a number of schemes aimed at accelerating the delivery of new medicines to patients, including the Lilly Research Awards Program and the Lilly Innovation Fellowship Awards.
Both of these programmes will see Lilly offering funding support and collaborative opportunities to academic researchers who are conducting studies that will support the company's drug development pipeline.
Lilly is also seeking to increase its own spending on innovative studies, having doubled its outlay on European research and development in the last decade.
Dr Jan Lundberg, executive vice-president for science and technology and president of Lilly Research Laboratories, said: "Finding innovative medicines that have clear, demonstrable value for those diseases where the unmet need is great ... is not only a scientific imperative, it's an economic one as well."
Last month, the company published its latest corporate responsibility report, showing that it was able to help more than 227,000 people through patient assistance programmes in 2010.
IMI funds platform to discover new medicines
The Innovative Medicines Initiative (IMI) has officially announced the
construction of an EU-wide public-private partnership, the "European Lead
Factory", to combine a comprehensive collection of candidate drug
molecules - a Joint European Compound Collection - with an industry-like
European Screening Centre.
Michel Goldman, IMI's Executive Director commented: "The joint
screening centre will give academic teams a unique opportunity to work in
conditions that meet industry standards, facilitating the translation of their
findings into actual treatments for patients. This shared facility, together
with the joint European Compound Collection, will greatly advance the chances
of success in the discovery of new medicines for researchers in Europe."
UCB CEO to lead Innovative Medicines Initiative board
UCB's chief
executive officer (CEO) Roch Doliveux has been chosen as the chairman of the
governing board of Europe's Innovative Medicines Initiative (IMI).
The IMI is a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations, which UCB has been a part of since its inception.
It currently funds 30 projects covering areas such as drug safety and efficacy, knowledge management and education, providing a combined budget of around 600 million euros (501.62 million pounds).
Mr Doliveux, who has been part of the IMI governing board since May 2010, will help the organisation to further its aim of promoting greater collaboration within the healthcare sector.
"The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs," he said.
Earlier this month, the company reported its financial results for 2011, announcing an annual revenue total of 3.25 billion euros.
The IMI is a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations, which UCB has been a part of since its inception.
It currently funds 30 projects covering areas such as drug safety and efficacy, knowledge management and education, providing a combined budget of around 600 million euros (501.62 million pounds).
Mr Doliveux, who has been part of the IMI governing board since May 2010, will help the organisation to further its aim of promoting greater collaboration within the healthcare sector.
"The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs," he said.
Earlier this month, the company reported its financial results for 2011, announcing an annual revenue total of 3.25 billion euros.
Εγγραφή σε:
Αναρτήσεις (Atom)